The impact of factors in work environment (especially shift and night work) on neoplasia  of female reproductive organs

Bartosz Bilski; Paweł Rzymski; Katarzyna Tomczyk; Izabela Rzymska

doi:10.20883/medical.e3

Authors

Bartosz Bilski Department of Preventive Medicine, Poznan University of Medical Sciences, Poland
Paweł Rzymski Department of Mother’s and Child’s Health, Poznan University of Medical Sciences, Gynecologic and Obstetrical University Hospital, Poznan, Poland
Katarzyna Tomczyk Department of Mother’s and Child’s Health, Poznan University of Medical Sciences, Gynecologic and Obstetrical University Hospital, Poznan, Poland
Izabela Rzymska Department of Social Sciences, Poznan University of Medical Sciences, Poland

DOI:

https://doi.org/10.20883/medical.e3

Keywords:

neoplasm, shift work, melatonin

Abstract

Shift work, due to disruption of circadian rhythms, can interfere with a number of physiological functions. It may lead to multiple pathologies (functional gastrointestinal disorders, peptic ulcer disease, hormonal disorders – including impaired melatonin secretion, cardiovascular disease, mental disabilities, neurological disorders etc.). In the last few years, we started to think about the association between disruption in melatonin secretion and the occurrence of certain malignancies. Authors describe and discuss pathophysiology, epidemiological and clinical data concerning influence of shift work to occurrence of some neoplasms.

Downloads

Download data is not yet available.

References

Karasek M, Pawlikowski M. Pineal gland, melatonin and cancer. Review. Neuroendocrinol Lett, 1999;20(3–4):139–144.

Schernhammer ES, Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004;90:941–943.

Glickman G, Levin R, Brainard GC. Ocular input for human melatonin regulation: relevance to breast cancer. Neuroendocrinol Lett. 2002;Supl 2:17–22.

Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investing Drugs. 2001;10:467–476.

Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7:189–203.

Bubenik GA, Blask DE, Brown GM, Maestroni GJ, Pang SF, Reiter RJ. Prospects of the clinical utilization of melatonin. Biol Signals Recept. 1998;7:195–219.

Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept. 2001;10:350–366.

Kozlova IV, Osadchuk MA, Kvetnoi IM. Changes in the APUD system of the large intestine as a risk factor for colorectal cancer. Klin Med. 1999;7:26–29.

Sandyk R, Anastasiadis PG, Anninos PA, Tsagas N. Is the pineal gland involved in the pathogenesis of endometrial carcinoma. Int J Neurosci. 1992;62:89–96.

Chuffa LG, Seiva FR, Fávaro WJ, Teixeira GR, Amorim JP, Mendes LO et al. Melatonin reduces LH, 17 beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reprod Biol Endocrinol. 2011;2:9:108.

Stevens RG, Schernhammer E. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 2005;14:551.

Tanavde VS, Maitra A. In vitro modulation of steroidogenesis and gene expression by melatonin: a study with porcine antral follicles. Endocr Res. 2003;29:399–410.

Maganhin CC, Simoes RS, Fuchs LF, Sasso GR, Simoes MJ, Baracat EC, Soares JM Jr. Melatonin influences on steroidogenic gene expression in the ovary of pinealectomized rats. Fertil Steril. 2014;102:291–8.

Dznelashvili NO, Kasradze DG, Tavartkiladze AG, Mariamidze AG, Dzhinchveladze DN. Expression of epidermal growth factor receptor and plasmatic level of melatonin in simple and complexendometrial hyperplasia. Georgian Med News. 2013;223:91–5.

Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol. 2001;36:297–310.

Diaz BL, Llaneza PC. Endocrine regulation of the course of menopause by oral melatonin: first case report. Menopause. 2008;15:388–92.

Navarro-Alarcón M1, Ruiz-Ojeda FJ, Blanca-Herrera RM, A-Serrano MM, Acuna Castroviejo D, Fernández-Vázquez G, Agil A. Melatonin and metabolic regulation: a review. Food Funct. 2014;5:2806–32.

Abdolsamadi H, Goodarzi MT, Ahmadi Motemayel F, Jazaeri M, Feradmal J, Zarabadi M, Hoseyni M et al. Reduction of Melatonin Level in Patients with Type II Diabetes and Periodontal Diseases. J Dent Res Dent Clin Dent Prospects. 2014;8:160–5.

Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 2001;22:45–47.

Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol. 2006;87:81–7.

Rabstein S, Harth V, Justenhoven C, Pesch B, Plöttner S, Heinze E, Lotz A, Baisch C, Schiffermann M, Brauch H, Hamann U, Ko Y, Brüning T; on behalf of the GENICA Consortium. Polymorphisms in circadian genes, night work and breast cancer: Results from the GENICA study. Chronobiol Int. 2014;17:1–8.

Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K, Ishizuka B. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancercell line. J Obstet Gynaecol Res. 2008;34:567–73.

Anisimov VN. The light-dark regimen and cancer development. Neuroendocrinol Lett. 2002;Supl 2:28–36.

Qin W, Lu W, Li H, Yuan X, Li B, Zhang Q, Xiu R. Melatonin inhibits IL1ß-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF?B activation. J Endocrinol. 2012;214:145–53.

Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood. 2006;108:518–24.

Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 2004;13: 936–943.

Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res. 2007;67:10618–22.

Oosthuizen JM, Bornman MS, Barnard HC, Schulenburg GW, Boomker D, Reif S. Melatonin and steroid-dependent carcinomas. Andrologia. 1989;21:429–431.

Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I et al. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 2003;95:825–828.

Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology. 2006;17:108–11.

Hansen J, Stevens RG. Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. Eur J Cancer. 2012;11:1722–9.

Kamdar BB, Tergas AI, Mateen FJ, Bhayani NH, Oh J. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138:291–301.

Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557–1562.

Poole EM, Schernhammer ES, Tworoger SS. Rotating night shift work and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:934–8.

Tynes T, Hannevik M, Andersen A, Vistnes AI, Haldorsen T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 1996; 2:197–204.

Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs. 2012;21:6, 819–31.

Witek A, Jęda W, Baliś M et al. Expression of melatonin receptors genes and genes associated with regulation of their activity in endometrial cancer. Gin Pol. 2015;4:248–255.